[1]李妍,曾欧,李琳, 等.冠心病患者血清 CysC、Lp-PLA2、MMP-9、PAI-1水平变化及临床意义[J].山东医药,2016,6(33):5-7. [2]张浩,徐兵,李泽浦.奥扎格雷对不稳定心绞痛患者血小板CD63、CD62P表达及血浆PAI-1、C-RP含量的影响[J].实用临床医药杂志,2012,16(11):85-87. [3]Jung RG, Simard T, Labinaz A, et al. Role ofSplasminogen activator inhibitor-1 in coronary pathophysiology.[J].Thromb Res. 2018 Apr;164:54-62.PMID:29494856 [4]Tang J, Zhu W, Mei X, et al. Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty.[J].J Orthop Surg Res. 2018 Jan 10;13(1):8.PMID:29321050 [5]詹莉,关秀军,邓斌.PAI-1与AMI患者冠状动脉内血栓形成溶栓后及复通的关系[J].心脏杂志,2016,8(6):711-713 [6]李琳,李芳,肖婷, 等.冠心病患者外周血RANTES、PAI-1和ADMA水平的变化及与GRACE评分的相关性分析[J].临床检验杂志,2015,9(8):577-580. [7]Gonias SL,SBanki MA,SGilder AS, et al. PAI1 blocks NMDA receptor-mediated effects of tissue-typeSplasminogenSactivatorSon cell signaling and physiology[J].J Cell Sci.S2018 Jul 26;131(14).PMID:29930084 [8]蒋守涛,黄华,陈蓓蓓, 等.参芎注射液对不稳定型心绞痛患者PAI 1表达的影响[J].中西医结合心脑血管病杂志,2015,10(15):1754-1755. [9]Iida K, Tani S, Atsumi W, et al. Association ofSplasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.[J].Coron Artery Dis. 2017 Nov;28(7):577-587.PMID:28692480 [10]Song C, Burgess S, Eicher JD , et al. Causal Effect ofSPlasminogen Activator InhibitorSType 1 on Coronary Heart Disease.[J].J Am Heart Assoc. 2017 May 26;6(6).PMID:28550093 [11]卢思稼.PAI-1在老年女性冠心病患者中的表达[J].中西医结合心脑血管病杂志,2014,12(3):373-373. [12]Chengji W,SXianjin F. Treadmill exercise alleviates diabetic cardiomyopathy by suppressingSplasminogen activator inhibitorSexpression and enhancing eNOS in streptozotocin-induced male diabetic rats[J].Endocr Connect.S2018 Apr;7(4):553-559.PMID:29555653 [13]Gilliot S, Sibon I, Mas JL, et al. Influence of on-going treatment with angiotensin-converting enzymeSinhibitorSor angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.[J].J Neurol. 2018 May;265(5):1166-1173.PMID:29549467 [14]戚德清,许康世.GPⅡb基因型急性心肌梗死患者介入治疗前后GMP-140、vWF和PAI-1水平[J].贵阳医学院学报,2014,13(1):57-60. [15]Chan SL,SBishop N,SLi Z, et al. Inhibition of PAI (Plasminogen Activator Inhibitor)-1 Improves Brain Collateral Perfusion and Injury After Acute Ischemic Stroke in Aged Hypertensive Rats[J].Stroke.S2018 Jul 10.PMID:29991657 [16]章怡祎,刘萍,励冬斐, 等.冠心康对ApoE基因敲除小鼠动脉粥样硬化的影响[J].上海中医药杂志 ,2012,15(11):80-83. [17]Pavlov MS,SNikoli?-Heitzler VS,SBabi? ZS, et al. Plasminogen activator inhibitor-1 activitySandSlong-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study[J].Croat Med JS2018 Jun;59 (3): 108-117PMID: 29972733 [18]古孜丽努尔-吐尼亚孜,哈斯也提-依部来音.丹参酮治疗老年冠心病的疗效及对血脂和血清 tPA、PAI -1的影响[J].现代中西医结合杂志,2016,7(23):2561-2563. [19]Li B,SHu J,SChen X. MicroRNA-30b protects myocardial cell function in patients with acute myocardial ischemia by targetingSplasminogen activator inhibitor-1[J].Exp Ther Med.S2018 Jun;15(6):5125-5132.SPMID:29805539 [20]章怡祎,刘萍,励冬斐, 等.冠心康对ApoE基因敲除小鼠动脉粥样硬化的影响[J].上海中医药杂志 ,2012,15(11):80-83.
|